Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Appyea Inc APYP

AppYea, Inc. is a digital health company, which is focused on the development of accurate wearable monitoring solutions to treat sleep apnea and snoring and fundamentally improve quality of life. The Company’s business plan focuses on two principal devices and an App in development: DreamIT and DreamIT PRO, and SleepX PRO. DreamIT is a biofeedback snoring treatment wristband, combined with the SleepX App and this wristband uses algorithms designed by SleepX combined with sensors to monitor physiological parameters during sleep. DreamIT PRO is a wristband for the treatment of sleep apnea using biofeedback in combination with the SleepX PRO app. The algorithms of SleepX PRO, combined with the wristband sensors, monitor sleep apnea events and additional physiological parameters during sleep, and when necessary. SleepX PRO is a medical application that is used to monitor breathing patterns in sleep and identify sleep apnea episodes without direct contact with the user.


OTCQB:APYP - Post by User

<< Previous
Bullboard Posts
Next >>
Post by Brice978on Sep 28, 2022 12:44pm
98 Views
Post# 34992540

North America is expected to dominate the Anti-snoring Devic

North America is expected to dominate the Anti-snoring DevicNorth America is expected to dominate the Anti-snoring Devices and The U.S. will hold a significant market share. Also, the North American market is expected to grow at the fastest CAGR over the forecast period and it is expected to reach $6.8 billion by 2023, progressing at a CAGR of 7.7% during 2018–2023.
<< Previous
Bullboard Posts
Next >>